Novartis Suspends Eight Clinical Trials After Three Patient Deaths in CAR-T Therapy
nashnova research
Novartis suspended all eight clinical trials of its experimental CAR-T therapy rap-cel in late August after three patients died from severe immune reactions. This means → the key expansion path for CAR-T — from cancer into autoimmune disease — has hit its first systemic safety barrier.
What happened?
Three patients died from severe immune reactions after receiving rap-cel; Novartis immediately halted all eight clinical trials involving the therapy.
The suspended studies span lupus, multiple sclerosis, and other autoimmune diseases — the core pipeline where Novartis is betting on CAR-T's next application.
Novartis says it is conducting a "comprehensive review," working with independent safety boards for each trial, and briefing regulators.
How can CAR-T kill a patient?
CAR-T — a therapy that extracts a patient's own immune cells, genetically engineers them to target and destroy abnormal cells, then infuses them back — is designed as a precision weapon.
The deaths were caused by hyperactivation of the re-infused immune cells, triggering massive inflammation and organ damage. In plain terms = the cells meant to strike surgically went into overdrive and attacked the patient's own body.
This complication has been documented before in cancer patients receiving CAR-T, but a trial suspension of this scale in the autoimmune space is unprecedented.
Why did Bristol Myers Squibb also halt its trial?
Bristol Myers Squibb then announced a precautionary pause of trials for zola-cel, its own autoimmune CAR-T therapy.
Both therapies target CD19 protein on the surface of immune cells — essentially the same "address label" CAR-T uses to find its targets — making their mechanisms closely related. This means → Novartis's safety event is not an isolated risk; it could implicate every therapy sharing the same target.
Bristol Myers Squibb said researchers found "transient and reversible inflammatory events" and is accelerating its review to resume enrollment.
What does this mean for the entire field?
Novartis and Bristol Myers Squibb each already market CAR-T products for cancer, priced at over $500,000 per treatment. Autoimmune disease is the next growth frontier both companies are counting on.
The central question: whether the rap-cel deaths are isolated cases or a mechanistic risk. This reflects a deeper issue — when CAR-T "migrates" from cancer to autoimmune disease, patients start from a fundamentally different baseline, and the safety margin may need to be redefined entirely.
Put simply = cancer patients are already critically ill, so high treatment risk is accepted; autoimmune patients typically face no immediate mortal threat, and the same level of side effects is measured by an entirely different ethical and regulatory yardstick.
市场有风险，内容仅供研究参考，不构成投资建议。